Aethlon Medical Q2 Results: Loss of $2.60 misses $2.25 estimate
Aethlon Medical (NASDAQ: AEMD) reported a Q2 fiscal 2027 loss of $2.60 per share, missing the analyst consensus estimate of $2.25. The company also announced a merger with North Immunology, Inc., which will see the combined entity operate under the North Immunology name, and Aethlon shareholders will receive contingent value rights for legacy Hemopurifier assets. Operating expenses rose significantly by 77.2% year-over-year due to merger-related costs.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.